Ad
related to: elidel pimecrolimus is indicated for
Search results
Results From The WOW.Com Content Network
Pimecrolimus is an immunosuppressant drug of the calcineurin inhibitor class used in the treatment of atopic dermatitis (eczema). It is available as a topical cream. It was developed and formerly marketed by Novartis under the trade name Elidel .
This page lists patient-reported quality of life surveys used in the field of medicine, pharmaceuticals, and other scientific trials.These surveys are patient-reported outcome measures, may be questionnaires or surveys, and may be used to evaluate patient satisfaction, symptoms, disease state, or psychological well-being.
Topical immunosuppressants like pimecrolimus and tacrolimus may be better in the short term and appear equal to steroids after a year of use. [66] Their use is reasonable in those who do not respond to or are not tolerant of steroids. [67] [68] Treatments are typically recommended for short or fixed periods of time rather than indefinitely.
The QoLIAD has also been utilized to assess the effectiveness of new treatments of atopic dermatitis. This includes studies looking into educational intervention, [4] [7] topical corticosteroids [8] and pimecrolimus. [9]
"The ascomycin macrolactam pimecrolimus (Elidel, SDZ ASM 981) is a potent inhibitor of mediator release from human dermal mast cells and peripheral blood basophils". The Journal of Allergy and Clinical Immunology. 108 (2): 275–280. doi: 10.1067/mai.2001.116865. PMID 11496246. Mollison KW, Fey TA, Krause RA, Thomas VA, Mehta AP, Luly JR (June ...
Pimecrolimus (Elidel), used to treat atopic dermatitis [118] ... gel, a topical corticosteroid indicated for the treatment of inflammation and pain following ocular ...
A class of medications called immunomodulators, such as pimecrolimus (Elidel) and tacrolimus (Protopic), affects the immune system. These medications have anti inflammatory and mild antifungal properties and are effective in treating seborrheic dermatitis.
Tacrolimus and a related drug for eczema (pimecrolimus) were suspected of carrying a cancer risk, though the matter is still a subject of controversy. The FDA issued a health warning in March 2005 for the drug, based on animal models and a small number of patients.